A carregar...
Barriers and solutions in cross-sector care for metastatic prostate cancer patients in Germany: a qualitative study on radioligand therapy
Abstract Background In December 2022, Pluvicto® (lutetium(177Lu)-vipivotide tetraxetan) received European Medicine Agency approval based on the Phase III VISION study as the first radioligand therapy (RLT) directed against prostate-specific membrane antigen (PSMA) and using Lutetium-177 (177Lu) for...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMC
2025-10-01
|
| Colecção: | BMC Health Services Research |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1186/s12913-025-13540-9 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|